(Q45765408)

15 December 2017

title

Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach (English)

1 reference

15 December 2017

author

Margarita Pons-salort

1

1 reference

15 December 2017

author name string

Véronique Letort

2

1 reference

15 December 2017

Michel Favre

3

1 reference

15 December 2017

Isabelle Heard

4

1 reference

15 December 2017

Benoit Dervaux

5

1 reference

15 December 2017

Lulla Opatowski

6

1 reference

15 December 2017

Didier Guillemot

7

1 reference

15 December 2017

language of work or name

English

0 references

publication date

13 December 2012

1 reference

15 December 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

15 December 2017

volume

31

1 reference

15 December 2017

issue

8

1 reference

15 December 2017

page(s)

1238-1245

1 reference

15 December 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Classification of papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

A review of human carcinogens--Part B: biological agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Continued impact of pneumococcal conjugate vaccine on carriage in young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

No coexistence for free: neutral null models for multistrain pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Vaccination and the evolutionary ecology of human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Modelling patterns of clearance of HPV-16 infection and vaccination efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

A systematic approach to virus-virus interactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Prevalence and implications of multiple-strain infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Vaccination against colonizing bacteria with multiple serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Multiple human papilloma virus types in cervical infections: competition or synergy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Concurrent and sequential acquisition of different genital human papillomavirus types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Clustering patterns of human papillomavirus genotypes in multiple infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Human papillomavirus infections among couples in new sexual relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.098

10.1016/J.VACCINE.2012.11.098

7 January 2021

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017